ERBB2 and neoplasm: Beyond ER itself, an increasing number of studies have also suggested that the crosstalk between prolactin receptor (PRLR) with ER and EGFR/HER2 pathways plays a crucial role inducing tumour proliferation and thus be associated with resistance to anti-HER2 treatment and with higher risk of relapse [86].